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Somatic mutations in human cancers are comprised of those that contribute to the oncogenic 
phenotype, driver mutations, and those that reflect the general patterns of exposure and disrepair 
but are otherwise noncontributory, passenger mutations. Distinguishing drivers that can be of low 
frequency in any given tumor type from often more numerous passengers is a key challenge. In this 
issue of Cancer Cell, Fröhling and colleagues tackle this challenge admirably for the known cancer 
gene FLT3 in acute myeloid leukemia—undertaking a systematic resequencing and functional 
validation approach, identifying important rare driver mutations as well as passenger mutations in 
patients negative for the more common activating mutations.
Open access under CC BY license.The first forays into large-scale sys-
tematic screening for somatic point 
mutations in human cancer have 
begun to reveal a heretofore undocu-
mented complexity and diversity of 
human cancer at the DNA sequence 
level (Greenman et al., 2007; Sjöb-
lom et al., 2006). There is growing 
evidence that, in addition to the more 
well-known culprits mutated com-
monly across various tumor types 
at appreciable prevalence, such as 
TP53, KRAS, and BRAF, there are 
very likely to be a substantial number 
of infrequently mutated cancer genes 
that contribute to oncogenesis. To fur-
ther complicate matters (in addition 
to this less than ideal configuration 
for fully exploiting cancer gene muta-
tions as inroads to therapeutics), the 
majority of somatic mutations identi-
fied in any given screen are very likely 
to be passenger events, with driver 
mutations scattered sparingly among 
them (Greenman et al., 2007). So, 
how will we sort the drivers from 
passengers, and what are the sys-
tematic approaches we will need to 
assemble to move forward and max-
imize translation of the information 
that will be coming from large-scale 
sequencing efforts?
The paper by Fröhling and col-
leagues (Fröhling et al., 2007) details 
one of the first systematic investiga-
tions of driver and passenger muta-
tions incorporating comprehensive 
target sequencing of a substantial 
number of cases and functional valida-
tion of variants observed. Their work concentrates on the role of mutations 
in FLT3, a receptor tyrosine kinase, 
in acute myeloid leukemia (AML). Of 
particular note, FLT3 mutations are 
already known to play an important 
role in AML (Small, 2006; Stirewalt 
and Radich, 2003). Internal tandem 
duplication mutations within the 
juxtamembrane (JM) autoinhibitory 
segment have been demonstrated 
in 25%–30% of adult AML cases 
(Stirewalt and Radich, 2003). Point 
mutations in the JM region have been 
show in a small number of cases. As 
well, activating mutations in the acti-
vation loop (AL) have been shown in 
an additional 7% of AML cases (Fröh-
ling et al., 2005). Importantly, patients 
with FLT3 mutant leukemias have 
worse prognosis with higher risks of 
relapse and shorter overall survival 
(Yanada et al., 2005).
Given the previous data, one might 
assume that the role of FLT3 mutation 
in AML is pretty well worked out. How-
ever, the authors took a laudably sys-
tematic approach to ascertain the full 
spectrum of FLT3 mutations in AML. 
A cohort of 222 pretreatment AML 
samples from adult patients nega-
tive for known activating mutations in 
FLT3 (as well as KIT and NRAS) were 
sequenced for all coding exons and 
consensus splice junctions of FLT3. 
A total of 17 heterozygous nucleo-
tide substitutions were identified. 
Of these, 5/17 had been previously 
reported as single nucleotide poly-
morphisms. Three of 12 unique vari-
ants were silent (synonymous) substi-Cancer Cell 12, Dtutions and were not pursued further; 
the remaining nine were missense 
(amino acid-changing) substitutions. 
Unfortunately, only one sample with a 
missense variant had available remis-
sion material to verify the somatic 
nature of the change. While the lack 
of confirmation of variants as somatic 
in any such study where variants are 
by definition rare is a point of concern, 
the specific sequence variants had not 
been detected in another 258 various 
samples where FLT3 coding exons 
have been fully sequenced in other 
studies. Also, two affected amino 
acid residues, V592 and R834, have 
had different variants reported (http://
www.sanger.ac.uk/genetics/CGP/
cosmic/). The authors pragmatically 
treat the nine variants as “candidate” 
driver mutations for the purposes of 
moving on to functional validation.
Here is where the study comes into 
its own. There has been a substantial 
body of work put into understanding 
the transforming and signaling prop-
erties of mutant FTL3 proteins. In par-
ticular, the BaF3 murine hematopoi-
etic transformation assay has proven 
a facile assay to detect transform-
ing/cytokine independence-inducing 
mutations in a variety of FLT3 and 
other tyrosine kinase alleles. Putting 
all nine candidate driver mutations 
through their paces, only four vari-
ants comprised of one extracellular 
domain, two JM domains, and one 
AL domain were able to induce IL-3-
independent growth. These four trans-
forming alleles were further shown to ecember 2007 ©2007 Elsevier Inc. 493
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FLT3 in immunoprecipitation experi-
ments. These data suggest that these 
are very likely to be driver mutations. A 
secondary screen of an additional 127 
adult AML cases for the presence of 
the four transforming alleles found one 
additional example for two of them, 
further supporting their identification 
as driver mutations.
The other five variant alleles were 
unable to induce growth factor inde-
pendence with all cells expressing 
the variants undergoing apoptosis 
upon IL-3 withdrawal. That these vari-
ants failed to score for transformation 
suggests that these are likely pas-
senger mutations. Further support to 
this interpretation is given by finding 
no further examples of the five vari-
ants in sequencing the relevant exons 
from 102 normal DNA samples. Also, 
the one proven somatic mutation in 
the full series is among the five puta-
tive passengers. The passenger vari-
ants were found in the extracellular 
domain (n = 3) and in the kinase and 
activation loops. Bioinformatics anal-
ysis results of all nine variants with 
two commonly used tools for assess-
ing potential functional impact of 
amino acid substitutions (SIFT, http://
blocks.fhcrc.org/sift/SIFT.html; and 
PMut, http://mmb2.pcb.ub.es:8080/
PMut/) were a bit of a mixed bag, with 
only 2/4 of the transforming variants 
predicted to alter function of the pro-
tein. One of the putative passenger 
variants, G831E, although negative in 
the BaF3 assay, was also predicted to 
alter function. While there is certainly 
some complementary information 
provided by a purely bioinformatics 
approach, the data provide strong 
rationale for coupling these data with 
functional assays. It remains a formal 
possibility that the passenger alleles, 
in particular the G831E, which affects 494 Cancer Cell 12, December 2007 ©20the highly conserved glycine in the 
canonical DFG motif of the AL, may 
have contextual oncogenic properties 
in the AML in which it occurred but 
that do not report in the BaF3 assay. 
As well, a number could be private 
rare polymorphisms. This being said, 
the application of a robust functional 
screen that reports transforming 
activity relevant to response to tar-
geted therapeutics provides compel-
ling evidence for the identification of 
relevant low-prevalence driver muta-
tions and ever-present passengers.
The authors go on to show that 
the four driver alleles differentially 
activate downstream signaling path-
ways. The AL allele R834Q was found 
to only activate ERK signaling, unlike 
the common D835Y mutation, which 
activated ERK, AKT, and STAT sig-
naling. Likewise, the two JM alleles 
were found to activate all three sig-
naling pathways, while the extracel-
lular domain allele was found to only 
activate ERK. These results suggest 
a marked subtlety in interaction of the 
FTL3 receptor with downstream tar-
gets modulated by the various muta-
tions. As well, the data suggest that 
activation of the MAPK pathway alone 
via FLT3 phosphorylation and ERK 
activation is sufficient for transforma-
tion. Furthermore, all four driver alleles 
conferred sensitivity to the potent FLT3 
TK inhibitor PKC412—an observation 
highlighting the potentially important 
clinical impact the identification of 
these alleles could have.
The work presented highlights 
several important points as we move 
forward into an era of cancer genome 
sequencing. First, in addition to the 
search for new cancer genes, we 
should revisit known cancer genes 
and fully evaluate their contribution, 
not only in the tumor types they are 
most associated with but also in a 07 Elsevier Inc.wide variety of cancers. Second, 
we will need robust approaches to 
identify relevant cancer gene muta-
tions in patient samples in clinically 
meaningful timeframes. Third, the 
assessment of driver and passen-
ger variants in this study was greatly 
facilitated by the target gene being 
a well-studied kinase. Applying this 
approach to nonkinase genes is going 
to be challenging and will require the 
development of increased through-
put cell biological assay platforms. 
This and other systematic screens 
are beginning to populate our lists of 
cancer genes and mutations with a 
wide spectrum of mutation types and 
prevalence in an increasing variety of 
genes. Understanding what the forces 
of in vivo selection are and how they 
are shaping the emergence and con-
tribution of these genes and mutations 
can only help us to better know the 
enemy, which may well be legion.
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